A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patient

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patient

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs SAR-113244 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 02 Jun 2016 Planned End Date changed from 1 Sep 2016 to 1 May 2017.
    • 02 Jun 2016 Planned primary completion date changed from 1 Sep 2016 to 1 May 2017.
    • 02 Jun 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top